Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas
Latest Information Update: 25 Mar 2025
At a glance
- Drugs Doxorubicin (Primary) ; LB 100 (Primary)
- Indications Fibrosarcoma; Leiomyosarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Nerve sheath neoplasms; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENHANCER
Most Recent Events
- 19 Aug 2024 According to a Lixte Biotechnology Holdings media release, the company expect to see the data from this first phase early in 2025
- 19 Jan 2024 Planned primary completion date changed from 8 Nov 2023 to 20 Jun 2025.
- 07 Jun 2023 According to a Lixte Biotechnology Holdings media release, 3 sites are active in Spain now and 3 additional sites will join the Phase 1b part in the coming weeks.